STERIS’ (TSE:STE – Free Report) – Investment analysts at Cormark upped their FY2025 EPS estimates for STERIS’ in a research note issued to investors on Thursday, March 13th. Cormark analyst B. Watson now expects that the company will post earnings per share of $0.52 for the year, up from their previous estimate of $0.38. Cormark currently has a “Moderate Buy” rating on the stock. Cormark also issued estimates for STERIS’’s FY2026 earnings at $0.61 EPS.
Separately, Atb Cap Markets raised shares of STERIS’ to a “strong-buy” rating in a report on Sunday, December 22nd.
STERIS’ Stock Performance
About STERIS’
STERIS’s MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe by providing innovative healthcare and life science product and service solutions around the globe.
Read More
- Five stocks we like better than STERIS’
- How to Plot Fibonacci Price Inflection Levels
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- 3 REITs to Buy and Hold for the Long Term
- 3 Must-Own Stocks to Build Wealth This Decade
- Dividend Payout Ratio Calculator
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for STERIS’ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS’ and related companies with MarketBeat.com's FREE daily email newsletter.
